<DOC>
	<DOCNO>NCT00719095</DOCNO>
	<brief_summary>There alarm increase abuse prescription opioids recent year . This project aim develop effective outpatient treatment prescription opioid ( PO ) abuse combine intensive behavioral therapy pharmacotherapy regimen buprenorphine detoxification naltrexone maintenance .</brief_summary>
	<brief_title>Effective Treatment Prescription Opioid Abuse</brief_title>
	<detailed_description>There alarm increase abuse prescription opioids recent year . This project aim develop effective outpatient treatment prescription opioid ( PO ) abuse combine intensive behavioral therapy pharmacotherapy regimen buprenorphine detoxification naltrexone maintenance . Aim 1 ) Conduct randomize , three-parallel-groups clinical trial ( Study 1 ) determine buprenorphine dose-tapering schedule prevents poor retention relapse undermine many opioid detoxification regimen . Aim 2 ) Conduct randomize , three-parallel-groups clinical trial ( Study 2 ) determine duration naltrexone therapy sustain opioid abstinence follow buprenorphine detoxification .</detailed_description>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>For inclusion propose study , subject must &gt; 18 year old good health . Subjects must meet DSMIV criterion opioid dependence FDA qualification criterion buprenorphine treatment , include history opioid dependence significant current opioid use ( i.e. , opioidpositive urine ) . Subjects must also seek willing accept opioid detoxification . Because primary focus propose research develop efficacious intervention prescription opioid abuse employ buprenorphine taper subsequent naltrexone maintenance , individual require ongoing opioid therapy pain chronic medical condition exclude participate . Individuals evidence active psychiatric disorder may interfere consent participation research ( e.g. , psychosis , manicdepressive illness , organic psychiatric disorder ) , significant medical illness ( e.g. , cardiovascular disease ) pregnant nursing exclude participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>prescription opioid</keyword>
	<keyword>opioid detoxification</keyword>
	<keyword>buprenorphine</keyword>
	<keyword>naltrexone</keyword>
	<keyword>community reinforcement approach</keyword>
	<keyword>prescription opioid abuse</keyword>
</DOC>